Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Inclusion Criteria: * Male and female patients with primary hyperlipidemia or mixed dyslipidemia * Patients for whom lipid-lowering therapy is indicated according to NCEP ATPIII * Patients who are naïve to statin or who are able to safely discontinue the use of all lipid-lowering agents for 4 weeks before randomization and throughout study participation Exclusion Criteria: * Homozygous familial hypercholesterolemia; * Any conditions which may cause secondary dyslipidemia. * Newly diagnosed or poorly controlled diabetes mellitus as defined by HbA1c \>9%